Enhanced Cell Line Development - Abzena (Cambridge)

AbZelectPRO™-KO: Robust GS Knockout Cell Line Platform

Ready to level up your cell line? This industry-leading platform combines Abzena’s optimized CLD workflow with Revvity’s CHOSOURCE™ host cell line and ProteoNic’s 2G UNic® vector technology, delivering reliable, high-quality titers in a trusted and easily scalable format.

Watch Video CLD Info Sheet

Leverage a Well-Established CLD Expression System: Discover AbZelectPRO™-KO

AbZelectPRO™-KO: Proven pedigree

>90 regulatory filings

AbZelectPRO™-KO: Commercial readiness

4 marketed therapeutics

AbZelectPRO™-KO: Long-term stability

Stable through ≥60 generations

AbZelectPRO™-KO unites Abzena’s track record in cell line development with Revvity’s CHOSOURCE™ GS knockout CHO-K1 host, ensuring seamless glutamine synthetase selection and superior genetic stability. By integrating ProteoNic’s 2G UNic® vector, the platform enhances transcription and translation efficiencies, enabling you to achieve target titers faster while maintaining your existing media and feeds.

Our New AbZelectPRO™-KO Platform

AbZelectPRO™-KO: Robust GS Knockout Cell Line Platform - Abzena

Achieve more with a well-established mammalian cell line:

  • High titers, fast – robust early-pool productivity accelerates IND-enabling studies
  • Consistent selection – GS knockout host drives reliable clone recovery
  • Stable expression – >60-generation stability ensures minimal drift
  • Regulatory confidence – underpins 4 approved therapeutics and >90 global filings
  • Streamlined workflow – familiar AbZelectPRO™ process with no added complexity
Contact Us

Supporting a Broad Range of Diverse Formats

AbZelectPRO™: Enhanced Cell Line Development - Abzena

Our dedicated & experienced CLD team recognizes the unique challenges posed by some formats & novel modalities as they continually evolve.

We can make the complex possible by supporting a broad range of diverse modalities:

  • Monoclonal & Bispecific Antibodies
  • Fc-Fusion Proteins
  • Antibody–Drug Conjugates
  • Multispecific Scaffolds
  • Complex Fusion Constructs
  • Glyco-Engineered Variants

Revvity’s Industry-Standard CHOSOURCE Cell Line

CHOSOURCE™ is a GS-knockout CHO-K1 host engineered for reliable selection and high-density growth. Its knockout of the endogenous GS gene drives strong selection pressure for your GOI, yielding robust, high-titer pools. Backed by a comprehensive cell-line history pack, CHOSOURCE™ has enabled over 90 IND filings and supports four marketed biologics. With a cell-line history pack already supporting multiple approved biologics, you gain a CMC package built on proven success.

Key features:

  • Glutamine synthetase knockout for powerful selection
  • Documented track record with advanced CMC data
  • Adaptable to any protein format and feeding regime
  • cGMP-proven lineage for rapid technology transfer

Enhanced with 2G UNic® by ProteoNic

We enhance productivity by partnering Revvity’s CHOSOURCE™ cell line with ProteoNic’s premium expression vector technology 2G UNic®. ProteoNic’s 2G UNic® vector offers the following benefits:

  • Optimized expression cassettes to maximize productivity through dual promoters combined to drive increased mRNA transcription per gene copy
  • Highly stable clones maintaining productivity beyond 90 generations through epigenetic stabilization, which reduces gene silencing for greater stability
  • Higher ribosome affinity for improved translation with optimized mRNA transport and mRNA stability allowing for more protein per mRNA molecule
  • Efficient GS selection marker compatible with CHOSOURCE cell Line
  • Proven track record with multiple programs moving towards regulatory approvals

Making the right decision for your cell line can be easy… achieve more with AbZelectPRO™-KO.

Ready to move forward? Contact Abzena

Related Insights

Whitepaper: Random Integration vs. Semi-Targeted Integration

Abzena's CLD experts explore two primary approaches - random integration and semi-targeted (or transposase) integration.

Learn More

Case Study: CHO Cell Line Performance with 2G UNic® Technology

Discover our case study that assesses the impact of 2G UNic® vector technology on protein expression in CHO cell lines

Learn More

Blog: AbZelectPRO™ - The Fast-Tracked CLD Platform of the Future

ProteoNic & Abzena experts discuss the benefits of our enhanced cell line development platform, AbZelectPRO™.

Learn More